Flagship Biosciences to demonstrate how its Computational Tissue Analysis platform advances clinical pipeline development at the Annual Meeting of the American Society of Clinical Oncology

Visit ASCO booth 25115 to learn more about Flagship’s decision support solutions.

May 15, 2017 – Westminster, CO – Flagship Biosciences, the leading partner for drug developers investigating tissue-based biomarkers, announced today that they will be exhibiting at the annual meeting of the American Society of Clinical Oncology (ASCO), June 2nd – 6th, at McCormick Place, Chicago, Illinois. The ASCO Annual Meeting offers informative educational and scientific sessions that highlight the latest in cancer care treatments.

Visit Flagship at booth #25115 to learn about how Flagship is contributing to advances in cancer therapeutics with the proprietary Computational Tissue Analysis (cTA™) platform and Precision Decision system designed to help drug developers gain clarity and confidence for clinical trial decisions.

If you would like to set-up a time to meet with Flagship representatives at ASCO, please email,

For a quick reference guide to help navigate you to Flagship’s booth at ASCO, follow the link here, ASCO Quickguide.

Flagship recently authored a white paper on the challenges and opportunities of immuno-oncology diagnostics. Copies of the paper will be available at Flagship’s ASCO booth. You can also download the paper here:

Follow Flagship on Twitter @flagshipbio for ASCO updates and news.

About Flagship Biosciences

Flagship Biosciences helps drug developers confidently define their path to success. By leveraging our unique computational Tissue Analysis (cTA™) and Data-Driven-Decision Support Platform, we provide quantitative and contextual tissue interpretation to make timely decisions. Flagship is proud to have served over 100 pharmaceutical and biotech companies.

For more information on how Flagship accelerates drug development, please visit the Company’s website:


Go Back